OCS Latest Press Releases

-- October 7, 2026 --

Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day Globe Newswire 1:59 AM

-- October 1, 2026 --

Oculis Joins the National Multiple Sclerosis Society's Campaign to End MS Globe Newswire 2:00 AM

-- September 30, 2026 --

Oculis Announces Resignation of Lionel Carnot from Board of Directors Globe Newswire 5:31 PM

-- August 24, 2026 --

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis Globe Newswire 4:00 AM

-- August 10, 2026 --

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company Globe Newswire 3:30 AM

-- August 6, 2026 --

Oculis Reports Q2 2026 Financial Results and Provides Company Update Globe Newswire 4:05 PM

-- August 3, 2026 --

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses Globe Newswire 4:00 AM

-- July 2, 2026 --

Oculis to Participate at the Piper Sandler Virtual Ophthalmology Conference Globe Newswire 4:00 AM

-- June 23, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS Globe Newswire 5:46 PM

-- June 18, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS PRNewswire 10:02 AM

-- June 17, 2026 --

OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm Globe Newswire 9:45 AM

-- June 16, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS Globe Newswire 5:04 PM

-- June 11, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS PRNewswire 10:01 AM

Oculis to Present Privosegtor at Upcoming Clinical Trials at the Summit 2026 Globe Newswire 4:00 AM

-- June 9, 2026 --

Oculis Announces First Patient Randomized in PREDICT-1 Registrational Trial of Licaminlimab, Advancing Precision Medicine in Dry Eye Disease Globe Newswire 4:00 AM

-- June 8, 2026 --

Oculis to Present at the 47th Annual Goldman Sachs Global Healthcare Conference Globe Newswire 3:25 PM

Oculis Holding AG (OCS) Securities Fraud Investigation - Levi & Korsinsky PRNewswire 9:00 AM

-- June 4, 2026 --

OCS Investors Have Opportunity to Join Oculis Holding AG Fraud Investigation with the Schall Law Firm Business Wire 4:31 PM

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS PRNewswire 10:00 AM

Levi & Korsinsky Announces Investigation of Securities Claims Against Oculis Holding AG (OCS) Globe Newswire 9:00 AM

-- June 3, 2026 --

OCS Investor Alert: Levi & Korsinsky Investigates Oculis Holding AG (OCS) for Potential Securities Fraud Business Wire 9:00 AM

-- June 2, 2026 --

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Oculis Holding AG - OCS Globe Newswire 5:08 PM

Oculis Holding AG Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information about Potentially Recovering Their Losses Globe Newswire 11:23 AM

OCS SHAREHOLDER INVESTIGATION: SueWallSt Investigates Oculis Holding AG for Possible Securities Law Violations PRNewswire 9:01 AM

-- June 1, 2026 --

Oculis Holding AG Investigation Initiated: Levi & Korsinsky Investigates the Officers and Directors of Oculis Holding AG (OCS) PRNewswire 3:31 PM

-- May 29, 2026 --

Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema Globe Newswire 3:05 PM

-- May 14, 2026 --

Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors Globe Newswire 4:05 PM

-- May 11, 2026 --

Oculis Reports Q1 2026 Financial Results and Provides Company Update Globe Newswire 4:07 PM